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 Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of selective and
potent BET (bromo and extra-terminal) inhibitors and their significant activity in diverse tumor models have rapidly
translated into clinical studies and have motivated drug development efforts targeting non-BET BRDs. However, the
complexmultidomain/subunit architecture of BRD protein complexes complicates predictions of the consequences of
their pharmacological targeting. To address this issue, we developed a promiscuous BRD inhibitor [bromosporine
(BSP)] that broadly targets BRDs (including BETs) with nanomolar affinity, creating a tool for the identification of
cellular processes and diseases where BRDs have a regulatory function. As a proof of principle, we studied the effects
of BSP on leukemic cell lines known to be sensitive to BET inhibition and found, as expected, strong antiproliferative
activity. Comparisonof themodulationof transcriptional profiles byBSPafter a short exposure to the inhibitor resulted
in a BET inhibitor signature but no significant additional changes in transcription that could account for inhibition of
other BRDs. Thus, nonselective targeting of BRDs identified BETs, but not other BRDs, as master regulators of context-
dependent primary transcription response.ce
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Bromodomains (BRDs) are acetyl-lysine–dependent protein interaction
modules that play a pivotal role in chromatin biology and control of gene
expression.ThehumanBRDfamily comprises 61diversedomains that are
present in mainly nuclear proteins. They often act as scaffolding proteins
but may also have catalytic functions, such as adenosine triphosphatase–
dependent helicase, histone acetyl, or methyl transferase activities (1).
Acetyl-lysine recognition ismediated by a binding cleft formedby four
canonical helices (aZ, aA, aB, and aC) and two connecting loop re-
gions (ZA and BC loops). This interaction site is highly druggable,
enabling the development of potent protein interaction inhibitors
(2, 3). BRD-containing proteins have been linked to a diversity of dis-
eases, in particular to cancer (2, 4). The first inhibitors developed to tar-
get BET (bromo and extra-terminal) proteins showed potent activity
not only in cancers that are dependent on chromosomal rearrangements
involvingBETsbutalso inotherdiverse cancer types (5,6).Thisunexpected6finding has been rationalized by the specific transcriptional down-
regulation of growth-promoting and antiapoptotic genes, including
key oncogenes, such as c-Myc (6). The strong growth-inhibiting prop-
erties of BET inhibitors therefore rapidly translated into clinical studies
that aim to examine their efficacy in oncology (2).
The success of BET inhibitors led to the development of programs
targeting other BRD proteins, and a number of potent and selective
chemical probes have now been published (5, 7–12). However, to date,
few phenotypic consequences of the inhibition of non-BET BRDs
have been reported. To evaluate the benefits of targeting other BRDs,
we developed a promiscuous BRD inhibitor with nanomolar potency
for 13 BRDs and low micromolar activity for 12 additional BRDs. In
analogy with the nonspecific kinase inhibitor staurosporine (13, 14),
we named this promiscuous inhibitor bromosporine (BSP). We evalu-
ated the consequences of BSP on transcription in leukemic cell lines, a
cancer type that has been studied well using BET inhibitors (6). We
found that BSP had effects on cell proliferation and clonogenic growth
that were similar to those of the pan-BET inhibitor (+)-JQ1 (henceforth
JQ1). Genome-wide transcriptional analysis using Illuminamicroarrays
revealed a pronounced BET signature after a short exposure to BSP. In
agreement with these data, the selective inhibitors of non-BET BRDs
showed only negligible effects on gene transcription, suggesting that
BETs—and not any of the other BRDs inhibited by BSP—are dominant
mediators of primary transcription response in leukemia. We believe
that BSP, similar to staurosporine, will be a versatile tool for studying
protein acetylation in chemical biology andwill inspire the development
of selective BRD inhibitors using related scaffolds.
For the design of BSP, we analyzed a comprehensive collection of
BRDstructures and complexes of BRDswith histone peptides (1, 15–20).
This analysis revealed similar binding modes of histone-derived pep-
tides across different BRD structural classes. A channel formed by the
ZA loop andhelixA is present inmost BRDstructures, but this pocket is1 of 16
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pothesized that BRD inhibitors with broad activity against BRDs could
target this conserved groove because it offers little possibility for
sequence-specific peptide binding while enhancing inhibitor affinity.
Expanding on our previous work on nonselective inhibitors based
on a tricyclic chemotype (21), we selected a similar triazolopyridazine
dicyclic core scaffold to explore the development of potent promiscuous
inhibitors.We rationalized that scaffold expansion toward the identified
binding groove and toward the BC loop would help avoid subfamily-
unique features, such as the WPF [tryptophan (W)–proline (P)–
phenylalanine (F)] shelf that would confer selectivity toward the BET
family (fig. S1B). Compounds developed as part of a small focused
library of dicyclic chemotypes, modified at two positions (fig. S1C), ex-
hibited broad activity in a thermal stability assay against a diverse set of
human BRD targets that comprised representative members of all BRD
structural subfamilies (fig. S2A). Several optimization cycles led to a com-
pound that potently inhibited most BRDs, which we named “BSP” and
selected for further characterization (Fig. 1A, fig. S2B, and table S1).http://adv
d from
 RESULTSBSP is a potent pan-BRD inhibitor in vitro
To confirm the promiscuous targeting of the human BRD family by
BSP, we screenedBSPwith biolayer interferometry (BLI) against a panel
of 42 recombinant biotinylated BRDs that covered all structural familiesPicaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016(fig. S2C). In agreement with our thermal melt data, BSP showed broad
activity against the BRDs of diverse families. To ascertain the predicted
promiscuous binding mode, we determined high-resolution crystal
structures with different human BRDs. In all cases, BSP was resolved
well in the high-resolution structures (Fig. 1B) and inserted into the
acetyl-lysine binding cavity of each BRD module. The binding mode
was conservedbetweenBRD9(Fig. 1C), the first BRDofBRD4[BRD4(1);
fig. S2D], and the second BRD of TAF1L [TAF1L(2); fig. S2E]. In all
cases, BSP exhibited a common bindingmode, whereby it engaged the
conserved asparagine [N100 in BRD9, N140 in BRD4(1), and N1602
in TAF1L(2)] while extending its sulfonamide substituent toward
the front of the ZA-loop binding cavity. The excellent shape com-
plementarity with diverse acetyl-lysine binding sites explained its
high binding potency, which we further characterized in solution
by isothermal titration calorimetry (ITC) (Fig. 1, D and E). For several
target subfamilies, BSP represents the most potent inhibitor developed
to date (Fig. 1D and Table 1). BSP exhibited affinity toward previously
untargetedBRDs, such asTAF1L(2) (KD=43nM), andprovided anovel
chemical starting point for BRDs that had been previously targeted with
only very weak compounds, such as P300/CBP-associated factor
(PCAF) (BSP KD = 4.7 mM).
BSP engages its target BRDs in cells
Next, we were interested to see whether BSP would exhibit similar
promiscuous binding to BRD-containing proteins in cells. To address o
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Fig. 1. BSP is a pan-BRD inhibitor in vitro. (A) Triazolopyridazine scaffold of BSP. (B) 2Fo− Fcmap of BSP bound to BRD4(1) contoured at 2s. (C) Complex of BSPwith the BRDof
BRD9. The compound adopts an acetyl-lysinemimetic posewithin the BRD cavity, initiating interactions with the conserved asparagine (N100). The sulfonamide function initiates
contacts with ZA-loop residues (G43), further stabilizing the interaction without displacing any of the structurally conserved water molecules (red spheres). (D) BSP binding with
low micromolar to nanomolar affinity to most structural classes within the human BRD family. Dissociation constants (KD) measured in-solution using ITC are displayed on the
humanBRD tree as spheres (size and color as indicated in the inset). BRD structural classes are annotatedwith romannumerals. (E) Overlay of ITCmeasurements of typically strong
BSP interactions with the BRDs of CECR2, BRD9, and TAF1L(2). Raw injection heats for the titrations of proteins into solutions of BSP are shown on the left panels. The right panel
shows the normalized binding enthalpies corrected for the heat of protein dilution as a function of binding site saturation (symbols as indicated in the figure). Solid lines represent a
nonlinear least-squares fit using a single-site bindingmodel. All titrationswere carried out in 50mMHepes buffer (pH 7.5; 25°C) and 150mMNaCl at 15°Cwhile stirring at 1000 rpm.2 of 16
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 this, we synthesizedBSP adductswith biotin tethered by a flexible linker.
The versatile pyridazine portion of BSP allowed positioning of a tag that
would point away from the central BRD cavity (Fig. 2A), resulting in
two biotinylated variants (Fig. 2B), which largely retained the in vitro
affinity toward BRDs (Table 2). The biotinylated BSP variants could en-
gage with CECR2 in human embryonic kidney (HEK) 293 cells stably
expressing 3×FLAG CECR2 (Fig. 2C). Encouraged by this result, we
used the biotin tag to extract and purify BRDs, applyingmass spectrom-
etry (MS) together with pull-down experiments using BSP biotin ad-Picaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016ducts. Although most BRD-containing proteins are expressed in
HEK293 cells, we observed enriched binding tomost high-affinity in vitro
targets of BSP (Fig. 2D and Table 3) and also identified binding partners
from larger complexes, such as the SWI/SNF BRD-containing proteins
SMARCA2/SMARCA4 and PB1, which were most likely enriched as a
result of a tight interaction with the BSP targets BRD7/BRD9 (22). We
next asked whether BSP directly engages its BRD targets in cells in the
acetyl-lysine competitive mode of action suggested by our structural
models. We used a fluorescence recovery after photobleaching (FRAP)Table 1. ITC of human BRDs with BSP. Titrations were carried out in 50 mM Hepes buffer (pH 7.5; 25°C) and 150 mM NaCl at 15°C while stirring at 1000 rpm.
Proteins were titrated into the ligand solution (reverse titration). Values are means ± SD.Protein [P] (mM) [L] (mM) KD (nM) DH
obs (kcal/mol) N TDS (kcal/mol) DG (kcal/mol)BAZ2A 433 15 3,745 ± 291 −3.04 ± 0.095 1.05 ± 0.025 4.12 −7.16BAZ2B 607 15 Weak bindingBRD1 440 13 1,653 ± 66 −7.32 ± 0.078 1.01 ± 0.008 0.30 −7.62BRD2(1) 271 25 97.1 ± 6.7 −7.90 ± 0.034 1.00 ± 0.003 1.34 −9.25BRD2(2) 235 25 50.3 ± 5.0 −5.46 ± 0.028 1.10 ± 0.003 4.18 −9.64BRD3(1) 275 20 91.7 ± 5.3 −10.02 ± 0.039 1.00 ± 0.002 −0.95 −9.08BRD3(2) 305 25 50.0 ± 4.7 −8.62 ± 0.041 1.11 ± 0.003 1.01 −9.63BRD4(1) 258 20 41.8 ± 2.8 −11.09 ± 0.038 0.94 ± 0.002 −1.36 −9.73BRD4(2) 270 20 39.7 ± 2.2 −6.60 ± 0.018 0.94 ± 0.001 3.17 −9.77BRDT(1) 228 20 40.2 ± 2.8 −13.16 ± 0.047 1.02 ± 0.002 −3.40 −9.76BRDT(2) 271 20 172.1 ± 10.6 −5.61 ± 0.028 1.00 ± 0.003 3.31 −8.92BRD9 251 25 41.7 ± 3.8 −8.75 ± 0.039 1.00 ± 0.002 0.98 −9.73BRPF1B 406 20 311.5 ± 11.2 −6.12 ± 0.021 1.00 ± 0.003 2.45 −8.57BRPF3 400 15 8,621 ± 381 −4.20 ± 0.123 1.08 ± 0.025 2.48 −6.68CECR2 202 16 8.0 ± 1.0 −17.28 ± 0.062 1.04 ± 0.002 −6.60 −10.68CREBBP 617 25 1,524 ± 116 −2.91 ± 0.041 1.03 ± 0.011 4.72 −7.64EP300 460 15 7,194 ± 501 −5.65 ± 0.265 0.97 ± 0.036 1.13 −6.78BPTF 230 15 1,887 ± 53 −10.09 ± 0.074 1.07 ± 0.005 −3.28 −6.80GCN5L2 336 15 Weak bindingPB1(3) 389 15 Weak bindingPB1(5) 604 15 14,225 ± 802 −3.19 ± 0.183 1.09 ± 0.053 3.20 −6.39PCAF 610 13 4,762 ± 459 −7.85 ± 0.454 0.95 ± 0.044 −0.83 −7.02SMARCA2 222 25 Weak bindingSMARCA4 400 13 19,685 ± 838 −9.05 ± 0.580 0.99 ± 0.055 −2.84 −6.21TAF1(1) 460 23 5,525 ± 199 −3.34 ± 0.046 0.98 ± 0.010 3.60 −6.94TAF1(2) 230 20 16.6 ± 2.7 −14.05 ± 0.095 0.98 ± 0.003 −3.80 −10.25TAF1L(1) 610 13 25,000 ± 2,027 −4.78 ± 0.778 1.00 ± 0.146 1.29 −6.07TAF1L(2) 250 20 42.7 ± 4.4 −12.48 ± 0.069 0.99 ± 0.003 −2.76 −9.72TIF1A 400 15 8,475 ± 431 −2.61 ± 0.088 1.09 ± 0.029 4.06 −6.673 of 16
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 technique to disrupt the interaction of full-length green fluorescent pro-
tein (GFP)–tagged BRD4 (Fig. 2, E and F) or full-length GFP-tagged
BRD9 (Fig. 2, G and H) with acetylated chromatin. In both cases, we
observed displacement of proteins from chromatin, as evidenced by the
fast recovery after bleaching (Fig. 2, F and H). In the case of BRD9, we
treated cells with the histone deacetylase inhibitor SAHA (suberoylani-
lide hydroxamic acid) to increase acetylation levels and to enhancePicaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016binding (Fig. 2H). For a representative selection of BRDs tested in the
presence of BSP, we observed a significant shortening of fluorescence
recovery times indicative of inhibition of chromatin-BRD interaction.
BSP inhibits growth of cancer cell lines
To further assess the effects of BSP on cellular systems, we profiled
this inhibitor against the National Cancer Institute (NCI) panel ofR
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Fig. 2. BSP engages its target BRDs in cells. (A) BSP binds to the BRD acetyl-lysine cavity, allowing for further functionalization toward the front channel within the ZA loop (Ra
vector annotated in orange) or the back of the pocket (Rb vector annotated in orange). The vectors are shown in the complex of BSPwith BRD4(1). (B) Two variants of biotinylated
BSP (BSP-a and BSP-b) were prepared to explore binding to human BRDs in cells by pull-down experiments. (C) Biotinylated BSP (BSP-a or BSP-b) immobilized onmagnetic beads
was used topull downhumanCECR2 fromFlp-In T-REx HEK293 cells stably expressing 3×FLAGCECR2. The protein captured fromwhole-cell lysatewas identified using anti-FLAG.
(D) Cell lysate fromHEK293T cells was incubatedwith biotinylated BSP (BSP-a or BSP-b) immobilized onmagnetic streptavidin beads in the presence or absence of 30 nmol of BSP
for 2 hours at 4°C. After pull-down and tryptic digestion with trypsin, proteins were identified in a TripleTOF 5600mass spectrometer. (Top) Normalized abundance of each BRD-
containing protein in HEK293 cells (data from Proteomics DB; https://www.proteomicsdb.org/). (Bottom) Ratio of peptide to peptide abundance in the presence and absence of
competing BSP, shown as a bar graph. BRD families are annotatedwith romannumerals. (E) FRAPevaluation of full-length GFP-tagged BRD4 dissociation from chromatin in U2OS
cells. Nuclei of DMSO-treated (top) or BSP-treated (1 mM; bottom) cells. Target regions of photobleaching are indicated with a white circle. Scale bar, 10 mm. FL-BRD4, full-length
BRD4; FL-BRD9, full-length BRD9. (F) Quantitative comparison of time to half-maximal fluorescence recovery for BRD4 FRAP studies using BSP (red bars) as a function of ligand
concentration. (G) FRAP evaluation of full-length GFP-tagged BRD9 dissociation from chromatin in U2OS cells. Nuclei of DMSO-treated (top) or BSP-treated (1 mM; bottom) cells in
the presence of 10 mMSAHA (added to increase the experimental window). Target regions of photobleaching are indicated with a white circle. Scale bars, 10 mm. (H) Quantitative
comparison of time to half-maximal fluorescence recovery for BRD9 FRAP studies using BSP (red bars) as a function of ligand concentration. Data in (F) and (H) representmeans ±
SEM (n = 30) and are annotated with P values obtained from a two-tailed t test (*P < 0.05 and ***P < 0.001).4 of 16
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 cancer cell lines (NCI-60). BSP exhibited strong growth inhibition in
all cancer types (fig. S3, A to I), including leukemia (fig. S3D). We
were particularly interested in this cancer type because we previously
observed strong inhibition of the growth of leukemia cell lines when
we used the pan-BET inhibitors JQ1 and PFI-1 (5, 7). We therefore
investigated the ability of BSP to inhibit the clonogenic growth and
proliferation of two acute myeloid leukemia (AML) cell lines
(MV4;11 and KASUMI-1), the hyperdiploid AML line OCI-AML3,
and the BCR-ABL–positive chronic myeloid leukemia (CML) cell line
K562, and we observed growth inhibition in the concentration range
100 to 500 nM (Fig. 3A and fig. S3J). Colony formation by the cells
was decreased at 500 nM BSP and severely inhibited at 1 mMBSP (Fig.
3B). Given the potent inhibition observed in colony formation, we also
compared the effect of BSP on clonogenic growth to the effect of the
pan-BET inhibitor JQ1, which was previously shown to potently and
effectively suppress proliferation in AML (6). K562 cells were relatively
resistant to BSP, similar to JQ1, whereas we measured nanomolar
median inhibitory concentration (IC50) values for both inhibitors in
MV4;11 and KASUMI-1 cells (fig. S4A). In summary, our data
showed that BSP potently inhibited colony formation and prolifera-
tion of leukemic cell lines with an efficacy that was slightly weaker
than that of pan-BET inhibitors, such as JQ1, in agreement with its
comparable in vitro potency toward BET family members.
BSP modulates transcription in leukemic cell lines
To better understand the contribution of BRDs to the transcriptional
landscape in leukemia, we compared the primary effects on trans-
cription after a short exposure to BSP or JQ1 in the three sensitive
AML cell lines (MV4;11, KASUMI-1, and OCI-AML3) and in the lessPicaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016sensitive CML cell line (K562). Principal components analysis revealed
that gene expression data sets of each cell line clustered together with no
obvious outliers, validating the quality of the gene expression data
(fig. S4B). Genes attenuated by either inhibitor were very similar
(Fig. 3C). Pairwise comparison of significantly up- and down-regulated
genes (P < 0.001 and fold change > 1.5) showed a strong correlation
between the two inhibitors, suggesting that BET BRDs may be princi-
pally responsible for the observed effect on transcription (Fig. 3D). Both
inhibitors resulted in very similar fold changes for themost significantly
regulated (P < 0.001 and fold change > 1.5) genes in each studied cell
line, although the effects of BSP and JQ1 on gene transcription were
highly context-dependent (Fig. 3E). In contrast, comparison between
sensitive cell lines and the less sensitive K562 cells revealed significant
differences in regulated genes.Many geneswith key functions in tumor-
igenesis, such as transcription factors (GATA1, FOXA3, and HOXA5),
tyrosine kinases (CSF1R and FES), and apoptosis regulators (BCL2 and
BCL6B), were differentially regulated in highly BET inhibitor–sensitiveTable 2. DTm shifts (°C) of biotinylated BSP (BSP-a and BSP-b) tested
against a panel of BET and other diverse BRDs. Compounds (final
concentration, 10 mM) were added to the proteins (final concentration,
2 mM); the temperature was increased from 25° to 96°C at a step of
3°C/min; excitation and emission filters for the SYPRO Orange dye were
set to 465 and 590 nm; and experiments were performed in triplicate.
Values are means ± SD.Protein DTm
obs (°C)BSP-a BSP-bBRD2(1) −7.5 ± 0.7 1.9 ± 0.5BRD2(2) −0.4 ± 0.2 3.0 ± 0.2BRD3(1) −2.7 ± 0.2 2.3 ± 0.3BRD3(2) −3.0 ± 0.1 3.1 ± 0.0BRD4(1) −2.7 ± 0.2 3.8 ± 0.3BRD4(2) −5.1 ± 0.0 1.8 ± 0.3BRDT(1) −5.0 ± 0.1 1.3 ± 0.3BRDT(2) 0.5 ± 0.1 0.9 ± 0.4CECR2 4.3 ± 0.0 7.4 ± 0.1CREBBP −3.1 ± 0.6 0.1 ± 0.4TAF1(2) −12.4 ± 0.1 1.9 ± 0.1TAF1L(2) 0.2 ± 0.1 2.9 ± 0.4Table 3. Relative abundance of BRD-containing proteins in HEK293
cells (data taken from Proteomics DB; https://www.proteomicsdb.
org/). Pull-down of human BRD-containing proteins with biotinylated BSP
(BSP-a and BSP-b), followed by competitive elution with BSP and MS,
resulted in enrichment of BSP-targeted BRDs.Protein Relative peptide
abundanceProtein Relative peptide
abundance293 BSP-a BSP-b 293 BSP-a BSP-bCECR2 — — — BRD7 4.51 10 5BPTF 4.31 — — BRD9 4.57 7.6 8GCN5L2 3.75 — — SP140L — — —PCAF — — — SP140 — — —BRD2 5.59 8 2 SP100 3.43 — —BRD3 5.04 2 2 SP110 2.71 — —BRD4 5.17 3 2 TIF1a 4.91 — —BRDT — — — TRIM33 5.34 — —BAZ1A 5.19 — — TRIM66 — — —BAZ1B 5.63 0.64 1.33 BAZ2A 4.25 — 3BRWD3 3.61 — — BAZ2B 3.21 — —PHIP 5.05 1.09 1.15 MLL 3.67 — —BRWD1 3.24 — 4 TRIM28 7.05 — —CREBBP 4.61 — — ZMYND8 4.4 — —EP300 4.87 — — TAF1 — 16 —BRD8 4.48 — — TAF1L — — —ATAD2 4.65 0.98 0.87 ZMYND11 — — —ATAD2B 3.68 0.90 1 ASH1L — — —BRD1 3.48 — — PB1 5.23 8.28 8BRPF1 3.6 — — SMARCA2 4.44 — —BRPF3 3.42 — — SMARCA4 5.53 8.8 55 of 16
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 cell lines (MV4;11 andOCI-AML3) in comparison to the K562 line (fig.
S4C). Independent validation of the effects of BSP and JQ1 by quanti-
tative real-time polymerase chain reaction (qRT-PCR) confirmed in-
hibitor effect in a dose-dependent fashion on the four leukemic cell
lines (fig. S4D). Among the most significantly deregulated genes were
histone clusters (linker, H2, and H3, including isoforms), which were
generally strongly up-regulated in K562 and down-regulated in BSP-
and JQ1-sensitive cells (fig. S5A).We suspected that a differential effect
on cell cycle may be a principal factor regulating sensitivity to BSP in
these cell lines. Transcription of histones is typically amplified by 20- toPicaud et al. Sci. Adv. 2016;2 : e1600760 12 October 201630-fold during the G1-to-S transition (23). We hypothesized that sensi-
tive cells may be arrested before this transition while less sensitive cells
are cycling normally, resulting in higher levels of histones.We therefore
investigated the effect of BSP on the cell cycle. Although BSP and JQ1
had little effect on cell cycle in the broad range of concentrations tested
in the less sensitive K562 cells (Fig. 4A), the sensitiveMV4;11 cells were
potently affected and exhibited distinct G1 arrest with reduced S-phase
populations (Fig. 4B).
Despite the differences across cell lines, we were surprised by the
high similarity in transcription response caused by both inhibitors andK562
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Fig. 3. BSP inhibits growth in leukemia cell lines. (A) BSP inhibits clonogenic growth in leukemia cell lines. K562, KASUMI-1, MV4;11, and OCI-AML3 in methylcellulose were
treatedwith vehicle (DMSO) or BSP (0.1, 0.5, or 1 mM) (n = 4). (B) Colony formation assay in K562, KASUMI-1, MV4;11, and OCI-AML3 cells using 0.1, 0.5, or 1.0 mMBSP (top) and the
number of cells counted after treatment of cells with BSP for 6 to 10 days (n = 4) (bottom). CFU, colony-forming units; ns, not significant. (C) Similarity comparison of significantly
expressed genes (P < 0.001 and fold change > 1.5) in the four cell lines after drug treatment. The heat map represents the intersect matrix for all pairwise comparisons (cell lines
and treatments) using euclidean distances and complete linkage after transformation of the intersect counts into similarity Jaccardmeasures. (D) Venn diagrams showing overlap
of the top statistically significant (Benjamini-Hochberg adjusted P<0.001) genes (up- or down-regulatedwith a fold change of >1.5) differentially expressed by BSP or the pan-BET
inhibitor JQ1 in four leukemia cell lines (K562, KASUMI-1, OCI-AML3, and MV4;11) after 8 hours of treatment with the inhibitor (0.5 mM) (top) and breakdown of the expression in
terms of up- and down-regulated genes for each cell line (bottom). (E) Heat map of log fold changes in the expression of the top 50 statistically significant genes in the four cell
lines tested, identified using Benjamini-Hochberg adjusted P< 0.001. Data in (B) representmeans ± SEM (n= 4) and are annotatedwith P values obtained froma two-tailed t test
(*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001).6 of 16
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 by the degree of the observed changes in gene expression (fig. S5B).
Given the small differences in individual genes, we decided to inves-
tigate the underlying gene ontologies enriched by each inhibitor in the
four cell lines. Surprisingly, between inhibitors, there were differences
in the underlying biological processes perturbed (fig. S6) or in the
cellular components affected (fig. S7A) within the same line. We also
performed a MetaCore analysis based on manually curated ontologies,
and we found similar enrichment of pathways or process networks
between inhibitors for the same line (fig. S7B and table S2). We next
performed gene set enrichment analysis (GSEA), seeking to identify
enrichment of similar functions between the four leukemia lines.
BSP-treated cells enriched several signatures from the Molecular Sig-Picaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016natures Database (MSigDB), including a very strong association with
signatures suggesting c-Myc down-regulation (figs. S8 and S9).
BSP exhibits a strong BET-like signature in leukemia
Wewere intrigued by the strong associationwith c-Myc down-regulation
signatures uncovered by GSEA. c-Myc transcriptional down-regulation
has been recognized as a dominant hallmark of BET inhibition in many
different tumor types (24), and c-Myc reexpression has been recently
linked toBET inhibitor resistance (25, 26). Zuber et al. (6) reported strong
transcriptional attenuation of the AML cell line THP1 after a 24-hour
treatment with JQ1.With these data, we constructed a gene set signature
using genes that were strongly down-regulated in THP1 cells (P < 0.001K562
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Scheme 1. Synthesis of BSP.
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 and fold change < −4) and interrogated our four cell lines with GSEA.
Both BSP and JQ1 elicited a strong response and enriched this THP1 sig-
nature in all four cell lines (fig. S10, A to D), suggesting that the effect of
the transcriptional response conferred byBSPoccurs throughBETBRDs.
To further test this, we explored a small gene set that was previously re-
ported to be regulated by JQ1 in neuroblastoma, multiple myeloma, and
AML (27), andwe found strong enrichment with BSP and JQ1 in all four
cell lines (fig. S10, E to H). Our data therefore suggest a dominant tran-
scriptional effect through BET proteins, despite the promiscuous target-
ing of several diverse BRD families by BSP.Picaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016Because BSP inhibits a large number of BRD-containing proteins,
we next addressed the relative expression level of these proteins in the
cell lines studied. We were surprised to find that most BSP target pro-
teins were expressed across all four cell lines (fig. S11A). We would ex-
pect BSP to bind to these proteins, reducing the effective concentration
of available BSP in the cells.We therefore investigated the effects of non-
BET BRD inhibitors specific for family III [CREBBP/EP300 using
I-CBP112 (28)], family IV [BRD7/BRD9 using LP99 (11) and BRPF1/
BRPF3 using OF1 (12)], and family V [BAZ2A/BAZ2B using GSK2801
(9)] BRD-containing proteins that are also targeted by BSP (fig. S11B).8 of 16
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 Weperformedgenome-wide expressionanalysis in thepan-BET inhibitor–
sensitive line MV4;11 and in the less sensitive line K562, focusing on
the same initial response window of 8 hours. We observed a striking
resemblance between BSP and JQ1 compared to all other inhibitors
tested, with a clear separation of transcriptional responses in both lines
(Fig. 4C). As expected,most of the significant genes attenuated (withP<
0.001 and fold change > 1.5) were due to BET BRD inhibition by JQ1;
however, a very small subset remained unique to BSP and did not
overlap with any of the other inhibitors, suggesting that another BSP
target or synergistic inhibition of BETs, in combination with other
BRD targets, was responsible for this population. This was also true
for some significant genes (P < 0.001), with smaller fold changes that
did not overlap with transcription responses observed using other
BRD inhibitors (fig. S12, A and B). We also noticed that attenuation
of themost significantly regulated genes was systematically different be-
tween BSP and JQ1 and all other inhibitor classes (fig. S13A). At the gene
level, there was a small overlap between inhibitor classes (fig. S13, B and
C); however, none of the non-BET inhibitors resulted in attenuation of
the previously reported JQ1 signature, which persisted between tissue
types (27) (Fig. 4D). To assess whether BSP and JQ1 would act synergis-
tically, we performed a cell toxicity study inwhich eight concentrations of
each inhibitor were systematically combined in the BET inhibitor–sensitive
(MV4;11) and less sensitive (K562) cell lines (fig. S13D). This study showed
that when both inhibitors were combined at concentrations significantly
lower than the individual median effective concentration (EC50) values
of the single compounds, survival of both cell lines was increased, whereas
at concentrations slightly below each individual EC50 value, we observed
synergistic effects of cellular toxicity (fig. S13E).
To obtain insights into time-dependent changes in gene expression
caused by pan-BET inhibition, we analyzed previously published data
on sensitive AML cells treated with JQ1 to define the transcriptional
response conferred by BETs after a long (24 hours) treatment. We per-
formed GSEA against all oncogenic signatures (MSigDB c6-gene set)
and constructed distinct directional networks for JQ1-treated THP1
cells, resulting in a complex network of signatures (fig. S14A). GSEA
followed by distinct directional network construction of BSP-induced
signatures revealed remarkable overlap with many of the late-response
JQ1-induced signatures observed in THP1 cells, but also significant en-
richment of gene sets associated with early response to BET inhibition,
such asdown-regulationof the epidermal growth factor receptor/mitogen-
activated protein kinase pathway (Fig. 4, B and C), whereas longer expo-
sure was characterized by transcriptional regulation of key transcription
factors of the E2F and HOX families.6DISCUSSION
The study presented here revealed a dominant function of BET BRDs
regulating gene transcription, compared to other selective BRD inhibi-
tors or the developed promiscuous BRD inhibitor BSP. Thus, inhibition
of non-BET BRDs is not likely to affect short-term gene expression, at
least in the cellular systems studied here. Selective inhibitors for the
BRDs present in SMARCA4/PB1 showed no significant effects on gene
expression but significantly contributed to the regulation of cell-specific
gene expression programs during cellular differentiation of trophoblasts
and stem cells (12). Similarly, inhibition of CREBBP/EP300 BRDs spe-
cifically affected differentiation of leukemia-initiating cells after pro-
longed exposure (28). These data suggest that non-BET BRDs may be
required for the organization of chromatin structure during cell differ-
entiation. In combination with genome-editing techniques, chemicalPicaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016tools (such as BSP) that target multiple BRDs can help rapidly establish
key potential BRD targets suitable for drug development. A recent study
demonstrated howCRISPR (clustered regularly interspaced short palin-
dromic repeats)/CAS9 can be used to identify BRD4 as an important
drug target that sustains murine AML cells (29). BSP represents a ver-
satile promiscuous pan-BRD inhibitor class that has limited off-target
effects (fig. S15 and table S3) and can be used as a front-line tool to
interrogate the role of the acetylation-dependent reading process in
cellular systems, leading to similar observations compared to genetic
approaches. Therefore, BSP is a valuable tool for the identification of
BRD-dependent cellular processes, helping accelerate cell-based studies
in this emerging target area.MATERIALS AND METHODS
Synthesis of BSP
BSP [ethyl (3-methyl-6-(4-methyl-3-(methylsulfonamido)phenyl)-
[1,2,4]triazolo[4,3-b]pyridazin-8-yl)carbamate] was prepared according
to Scheme 1.
Intermediate materials were prepared as follows:
3,6-Dichloropyridazin-4-amine (2): A stainless steel reaction vessel
was chargedwith 3,4,6-trichloropyridazine (1) (1 g, 5.46mmol) and ab-
solute ethanol saturated with ammonia (40 ml) at 0°C. The vessel was
sealed, and the mixture was heated at 125°C for 7 hours. The reaction
mixture was evaporated to dryness, and the crude product was recrys-
tallized from water to yield 2 (547 mg, 61%). MS [electrospray ioniza-
tion (ESI)]: mass/charge ratio (m/z) for [C4H3Cl2N3+H]
+—calculated,
164 (2× 35Cl), 166 (35Cl/37Cl), and 168 (2× 37Cl); found, 163.9, 165.9,
and 167.8.
6-Chloro-3-hydrazinylpyridazin-4-amine (3): Dichloride 2 (547mg,
3.33 mmol) and hydrazine (10 ml) were heated to reflux for 3 hours.
The mixture was cooled to room temperature, and water (5 ml) was
added. The resulting crystalline precipitate was collected, washed with
coldwater, anddried under reduced pressure to obtain 3 (210mg, 40%).
MS (ESI): m/z for [C4H6ClN5+H]
+—calculated, 160 (35Cl) and 162
(37Cl); found, 159.9 and 161.9.
6-Chloro-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-amine (4):
Hydrazine 3 (210 mg, 1.32 mmol) and acetic acid (3 ml) were heated to
reflux for 5 hours. Ice water was added, and the resulting precipitate was
collected by filtration. Recrystallization of the crude product frommethanol
afforded the desired 4 (200mg, 82%).MS (ESI):m/z for [C6H6ClN5+H]
+—
calculated, 184 (35Cl) and 186 (37Cl); found, 184.1 and 186.1.
tert-Butyl (6-chloro-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8- yl)
carbamate (5): Boc2O (7.1 g, 32.9 mol) and 4-dimethylaminopyridine
(DMAP) were added to a solution of amine 4 (2 g, 10.9 mmol) in tetra-
hydrofuran (THF) (60 ml) at 0°C. The mixture was allowed to warm to
room temperature, and the reaction progress was monitored by thin-
layer chromatography (TLC). Upon completion, the mixture was con-
centrated under reduced pressure, and the resulting solution was diluted
with EtOAc, washed with brine, and dried (Na2SO4). The solvent was
removed in vacuo, and the residue was purified by flash column chro-
matography (petroleum ether/EtOAc, 1:2) to yield 5 (1.2 g, 40%). MS
(ESI): m/z for [C11H14ClN5O2+H]
+—calculated, 284.1 (35Cl) and 286.1
(37Cl); found, 284.1 and 285.0.
tert-Butyl (3-methyl-6-(4-methyl-3-nitrophenyl)-[1,2,4]triazolo[4,3-
b]pyridazin-8-yl)carbamate (7): Pd(PPh3)4 (61 mg, 10% eq) and
K2CO3 (182 mg, 1.32 mmol) were added to a mixture of chloride 5
(150 mg, 0.53 mmol) and boronic acid 6 (287 mg, 1.59 mmol) in
dioxane/water (5.5 ml, 10:1 v/v), and the resulting mixture was heated9 of 16
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 at 120°C under Ar. The reaction was monitored by TLC. Upon comple-
tion, water was added, and the combined aqueous layers were extracted
with dichloromethane (DCM). The organic layers were combined and
dried (Na2SO4). The solvent was removed in vacuo, and the residue was
purified by flash column chromatography (DCM/MeOH, 50:1) to give
compound 7 (90 mg, 44%). MS (ESI): m/z for [C18H20N6O4+H]
+—
calculated, 385.2; found, 385.1. 1H nuclear magnetic resonance (NMR)
(CDCl3): d 8.62 (1H, d, J = 1.8 Hz), 8.22 (1H, brs), 8.14 to 8.10 (2H, m),
7.48 (1H, d, J = 8.1 Hz), 2.88 (3H, s), 2.67 (3H, s), and 1.57 (9H, s).
3-Methyl-6-(4-methyl-3-nitrophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-
8-amine (8): Trifluoroacetic acid (2 ml) was added to a solution of car-
bamate 7 (80 mg, 0.21 mmol) in DCM (10 ml), and the mixture was
stirred at room temperature. The reaction was monitored by TLC.
Upon completion, the mixture was concentrated under reduced
pressure, and the residue was purified by flash column chromatog-
raphy (DCM/MeOH, 30:1) to yield 8 (64 mg, 100%). MS (ESI): m/z
for [C13H12N6O2+H]
+—calculated, 285.1; found, 285.3. 1H NMR
[dimethyl sulfoxide (DMSO)–d6]: d 8.49 (1H, d, J = 1.8 Hz), 8.19
(1H, dd, J = 1.9 Hz, 8.0 Hz), 7.68 (1H, d, J = 8.1 Hz), 6.65 (1H, s),
2.70 (3H, s), and 2.60 (3H, s).
Ethyl (3-methyl-6-(4-methyl-3-nitrophenyl)-[1,2,4]triazolo[4,3-b]
pyridazin-8-yl)carbamate (9): Triethylamine (0.35 ml, 2.46 mmol)
was added to a solution of amine 8 (348 mg, 1.23 mmol) in dry THF
(20 ml) at 0°C. After 30 min, ethyl chloroformate (0.34 ml, 2.46 mmol)
was added, and the reactionmixture was warmed to room temperature.
The reaction was monitored by TLC. Upon completion, water (30 ml)
was added, and the aqueous phase was extracted with DCM. The com-
bined organic layers were dried (Na2SO4), and the solvent was removed
under reduced pressure. The crude product was purified by flash column
chromatography (EtOAc/petroleumether, 1:1) to yield9 (100mg, 23%).MS
(ESI):m/z for [C16H16N6O4+H]
+—calculated, 357.1; found, 357.1. 1HNMR
(CDCl3):d 8.60 to8.59 (2H,m),8.19 (1H, s), 8.10 (1H,dd, J=1.8Hz,8.1Hz),
7.52 (1H,d, J=8.1Hz), 4.35 (2H,q, J=7.1Hz), 2.85 (3H, s), 2.67 (3H, s), and
1.38 (3H, t, J = 7.1 Hz).
Ethyl (6-(3-amino-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-
b]pyridazin-8-yl)carbamate (10): SnCl2 hydrate (287 mg, 1.28 mmol)
was added to a solution of nitrobenzene 9 (91 mg, 0.26 mmol) in EtOH
(10 ml). The reaction mixture was heated to reflux and monitored by
TLC. Upon completion, the solvent was removed under reduced pres-
sure, and the crude product was purified by flash column chromatog-
raphy (DCM/MeOH, 50:1) to yield 10 (74 mg, 87%). MS (ESI):m/z for
[C16H18N6O2+H]
+—calculated, 327.1; found, 326.9. 1HNMR (CDCl3):
d 8.36 (1H, brs), 8.13 (1H, s), 7.32 to 7.30 (2H,m), 7.16 (1H, d, J=8.1Hz),
4.33 (2H, q, J = 7.2Hz), 3.80 (2H, brs), 2.84 (3H, s), 2.23 (3H, s), and 1.37
(3H, t, J = 7.2 Hz).
Ethyl (3-methyl-6-(4-methyl-3-(methylsulfonamido)phenyl)-
[1,2,4]triazolo[4,3-b]pyridazin-8-yl)carbamate (11) (BSP): Methane-
sulfonyl chloride (2 eq) was added to a solution of amine 10 (1 eq) in
DCM(0.037M), followed by addition of pyridine (0.6 eq). The resulting
mixturewas stirred at room temperature. The reactionwasmonitoredby
TLC. Upon completion, water was added, and the aqueous layer was
extracted with DCM. The organic layers were combined and dried
(Na2SO4). The solvent was removed, and the residue was purified by
flash column chromatography (DCM/MeOH, 30:1) to give BSP 11
(78%). MS (ESI): m/z for [C17H20N6O4S+H]
+—calculated, 405.1;
found, 405.5. 1H NMR (CDCl3): d 8.93 (1H, brs), 8.14 (1H, s), 8.10
(1H, d, J = 1.8 Hz), 7.70 (1H, dd, J = 1.8 Hz, 7.8 Hz), 7.64 (1H, brs),
7.32 (1H, d, J = 8.1Hz), 4.30 (2H, q, J = 7.1Hz), 3.09 (3H, s), 2.82 (3H, s),
2.44 (3H, s), and 1.34 (3H, t, J = 7.2 Hz).Picaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016Cloning, protein expression, and purification
Human BRDs were subcloned into bacteria-expressing vectors [pNIC28-
Bsa4 (GenBank EF198106) and pNIC-Bio2 (GenBank JF912191)], ex-
pressed, andpurified as previously describedbyFilippakopoulos et al. (1).
Thermal stability assay (Tm shift)
Thermalmelting experiments were carried out using anMx3005PReal-
Time PCR machine (Stratagene). Proteins were buffered in 10 mM
Hepes buffer (pH 7.5) and 500 mM NaCl and assayed on a 96-well
plate at a final concentration of 2 mMin a volume of 20 ml. Compounds
were added at a final concentration of 10 or 100 mM. SYPRO Orange
Protein Gel Stain (Molecular Probes) was added as a fluorescence probe
at a dilution of 1:1000. Excitation and emission filters for the SYPRO
Orange dye were set to 465 and 590 nm, respectively. The temperature
was raised from 25° to 96°C at a step of 3°C/min, and fluorescence read-
ings were taken at each interval. The temperature dependence of the
fluorescence during the protein denaturation processwas approximated
by the equation
y Tð Þ ¼ yF þ yU  yF
1þ eDuGðTÞ=RT
whereDuG is the difference in unfolding free energy between the folded
state and the unfolded state, R is the gas constant, and yF and yU are the
fluorescence intensities of the probe in the presence of completely folded
and unfolded proteins, respectively (30). The baselines of the denatured
and native states were approximated by a linear fit. The observed tem-
perature shifts (DTm
obs) were recorded as the difference between the
transition midpoints of sample and reference wells containing proteins
without ligands in the same plate and were determined by nonlinear
least-squares fit. Temperature shifts (DTm
obs) for three independent
measurements per protein/compound are summarized in table S1
and Table 2.
Biolayer interferometry
Experiments were performed on an Octet RED384 System (FortéBio)
at 25°C in 20 mM Hepes (pH 7.5), 150 mM NaCl, and 0.5 mM tris(2-
carboxyethyl)phosphine using the FortéBio data acquisition software
V.7.1.0.100. Biotinylated BRDs were immobilized onto Super Strepta-
vidin biosensors (Super StreptavidinDip andReadBiosensors for kinetic
no. 18-0011; FortéBio), preequilibrated in the BLI buffer, and quenched in
a solution of 5 mMbiotin (baseline equilibration for 60 s, peptide loading
for 240 s, and quenching for 60 s; shake speed of 1000 rpmat 25°C). The
immobilized proteins were subsequently used in association and disso-
ciation measurements performed within a time window of 600 s
(baseline equilibration for 60 s, association for 600 s, and dissociation
for 600 s; shake speed of 1000 rpm at 25°C). Interference patterns from
protein-coated biosensors without proteins were used as controls. After
referencing corrections, the subtracted binding interference data were
analyzed using the FortéBio data analysis software V.7.1.0.38 (provided
with the instrument) following the manufacturer’s protocols.
Isothermal titration calorimetry
Experiments were carried out on an ITC200 microcalorimeter from
MicroCal LLC (GE Healthcare) equipped with a washing module, a
reaction cell (volume of 0.2003 ml), and a 40-ml microsyringe. Ex-
periments were carried out in ITC buffer [50 mM Hepes (pH 7.5;
25°C) and 150 mM NaCl] at 15°C while stirring at 1000 rpm. The
microsyringe was loaded with a solution of a protein sample (200 to10 of 16
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 650 mM in ITC buffer) and was carefully inserted into the calorimetric
cell, which was filled with the compound (0.2 ml, 13 to 25 mM in ITC
buffer). The systemwas first allowed to equilibrate until the cell tempera-
ture reached 15°C, and an additional delay of 60 s was applied. All titra-
tions were conducted using an initial control injection of 0.3 ml, followed
by 38 identical injections of 1 ml for a duration of 2 s (per injection) and
with a spacing of 120 s between injections. The titration experiments
were designed to ensure complete saturation of the proteins before the
final injection. The heats of dilution for the proteinswere independent of
their concentrations and corresponded to the heats observed from the
last injection, after saturation of ligand binding, thus facilitating estima-
tion of the baseline of each titration from the last injection. The collected
data were corrected for protein heats of dilution (measured in separate
experiments by titrating the proteins into ITC buffer) and deconvoluted
using the MicroCal Origin software (supplied with the instrument) to
yield enthalpies of binding (∆H) and binding constants (KB), as previ-
ously described in detail by Wiseman et al. (31). Thermodynamic pa-
rameters were calculated using the basic equation of thermodynamics
(∆G = ∆H − T∆S = −RTlnKB, where ∆G, ∆H, and ∆S are the changes
in free energy, enthalpy, and entropy of binding, respectively). In all
cases, a single binding site model was used (supplied with theMicroCal
Origin software package). Dissociation constants and thermodynamic
parameters are listed in Table 1.
Crystallization
Aliquots of the purified proteins were set up for crystallization using a
mosquito crystallization robot (TTP Labtech). Coarse screens were typ-
ically set up onto Greiner three-well plates using three different drop
ratios of precipitant to protein per condition (100 + 50, 75 + 75, and
50 + 100 nl). Initial hits were optimized, further scaling up the drop sizes.
All crystallizations were carried out using the sitting-drop vapor diffu-
sion method at 4°C. BRD4(1) crystals with BSP were grown by mixing
200 nl of the protein (9.9 mg/ml and 5 mM final ligand concentration)
with 100 nl of reservoir solution containing 0.20M sodium/potassium
tartrate, 0.1 M BT-propane (pH 8.5), 20% polyethylene glycol (PEG)
3350, and 10% ethylene glycol. TAF1L(2) crystals with BSPwere grown
by mixing 150 nl of the protein (11.2 mg/ml and 10 mM final ligand
concentration) with 150 nl of reservoir solution containing 0.1MMMT
[mixture of DL-malic acid and 2-(N-morpholino)-ethanesulfonic acid
monohydrate] (pH 7.5) and 63% 2-methyl-2,4-pentanediol. BRD9
crystals with BSP were grown by mixing 100 nl of the protein
(28 mg/ml and 10 mM final ligand concentration) with 200 nl of
reservoir solution containing 0.1 M bis-tris (pH 5.5), 0.2 M NaCl, and
25% PEG3350. Diffraction-quality crystals grew within a few days.
Data collection and structure solution
BRD4(1) crystals were cryoprotected using the well solution supple-
mented with additional ethylene glycol and were flash-frozen in liquid
nitrogen. Data were collected in-house on a Rigaku FRE rotating anode
system equippedwith an R-AXIS IV detector at 1.52 Å [BRD4(1)/BSP],
at Diamond beamline I02 at a wavelength of 0.9795Å [TAF1L(2)/BSP],
or at Diamond beamline I04 at a wavelength of 0.9795 Å (BRD9/BSP).
Indexing and integration were carried out using XDS (32, 33), and
scaling was performed with Scala (34). Initial phases were calculated
by molecular replacement with PHASER (35) using the known models
of BRD4(1), TAF1L(2), or BRD9 [Protein Data Bank (PDB) accession
codes 2OSS, 3HMH, and 3HME, respectively]. Initial models were built
by ARP/wARP (36) followed by manual building in Coot (37). Refine-
ment was carried out in REFMAC5 (38). Thermal motions were ana-Picaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016lyzed using TLSMotion Determination (39), and hydrogen atoms were
included in late refinement cycles. Data collection and refinement sta-
tistics are found in table S4. The model and structure factors have been
deposited with PDB accession codes 5IGK [BRD4(1)/BSP], 5IGL
[TAF1L(2)/BSP], and 5IGM (BRD9/BSP).
BSP pull-down assay
BSPpull-downswere performedusing two different biotinylated probes
(BSP-a and BSP-b) from a lysate of ~2 × 107HEK293T cells per sample.
Briefly, to the frozen HEK293T cell pellet, 1.6 ml of ice-cold lysis buffer
[50 mMHepes-NaOH (pH 8.0), 2 mM EDTA, 0.1% NP-40, 10% glyc-
erol, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, and
Sigma Protease Inhibitor Cocktail (P8340, 1:500) with 300 mM KCl]
was added per 15-cm plate of cells, and the frozen pellet was gently re-
suspended. Samples were subjected to a freeze/thaw cycle on dry ice until
completely frozen (5 to 10min) and then transferred to a 37°Cwater bath
with agitation until only a small amount of ice remained. Samples were
sonicated for 30 s (10 s on–2 s off cycles at an amplitude of 0.35) using a
Qsonica 125-W sonicator equipped with a 1/8-inch probe to shear DNA.
Benzonase (1ml, 250U/ml; E1014; Sigma-Aldrich)was then added to each
sample and incubated at 4°C for 1 hour to further digest chromatin. The
resulting samples were centrifuged at 14,000 rpm (20,873g) for 20min at
4°C, and the supernatantwas transferred to fresh 2-ml tubes. Biotinylated
BSP probes [50 nmol conjugated to 20 ml ofMyOne Streptavidin C1Dy-
nabeads (65002; Invitrogen) for at least an hour in 1× phosphate-buffered
saline (PBS)]werewashedwith lysis buffer, and an equal bead volumewas
subsequently aliquoted between centrifuged cell lysates. The mixture was
incubated for 2 hours at 4°C with gentle agitation (nutator) with or with-
out competition from 30 nmol of BSP. Beads were then pelleted by cen-
trifugation (1000 rpm for 5 s), and tubes were placed on a cold magnetic
rack (on ice) to collect the beads on the side of the tubes. The supernatant
was removed slowly with a pipette, and the beads were washed once with
1 ml of cold lysis buffer with 300 mM KCl and washed twice with lysis
buffer containing 100 mM KCl. The beads were then transferred to a
fresh 1.7-ml tubewith 1ml of 20mMtris-HCl (pH8.0) and 2mMCaCl2.
After the last wash, the samples were quickly centrifuged, and the last
drops of liquid were removed with a fine pipette.
Binding of BSP to CECR2 was evaluated in Flp-In T-REx HEK293
cells stably expressing 3×FLAGCECR2 (accession no. BC166664) or an
empty 3×FLAG control (using lysis buffer containing 300 mM KCl).
After pull-down, proteins were eluted off the beads by adding 40 ml
of 2× Laemmli buffer and heating the samples to 65°C for 15 min.
The samples were then cooled to room temperature, quickly centri-
fuged, and placed on a magnetic rack to collect the beads on the side
of the tubes. The supernatants were then transferred to fresh tubes
and stored at −40°C until Western blots were performed. One per-
cent of input and 25% of purified proteins were separated by SDS–
polyacrylamide gel electrophoresis and transferred onto nitrocellulose
membranes. The membranes were blocked in tris-buffered saline
containing nonfat milk (5 mg/ml) and 1% Tween 20 for 1 hour at
room temperature. Blots were probed for FLAG (1:5000; F1804;
Sigma-Aldrich) or b-tubulin (1:5000; E7;Developmental StudiesHybri-
domaBank) at theUniversity of Iowa. Detection on filmwas performed
by chemiluminescence using the LumiGLO reagent (1:20; 7003; Cell
Signaling Technology).
Trypsin digestion of affinity-purified proteins
After pull-down onmagnetic beads, samples were resuspended in 7.5 ml
of 20 mM tris-HCl (pH 8.0) containing 500 ng of trypsin (Trypsin11 of 16
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 Singles, T7575; Sigma-Aldrich), and the suspension was incubated at
37°C with agitation overnight on an angled rotating wheel (~15 hours).
After this first incubation, samples were quickly centrifuged and then
magnetized, and the supernatants were transferred to a fresh tube.
Another 250 ng of trypsin was added [in 2.5 ml of 20 mM tris-HCl
(pH 8.0)], and the resulting sample was incubated at 37°C for 3 to 4 hours
without agitation. Formic acid was then added to a final concentration
of 2% (from 50% stock solution) and stored at −80°C.
MS analysis
Pull-down samples and controls were analyzed by MS, as previously
described by Barsyte-Lovejoy et al. (40). Briefly, 5 ml of each sample
(representing ~50% of the sample) was directly loaded at a flow rate of
400 nl/min onto a 75 mm × 12 cm emitter packed with a 3-mmReproSil-
Pur C18-AQ (Dr.MaischGmbHHPLC). The peptides were eluted from
the columnover a 90-mingradient generatedby aNanoLC-Ultra 1DPlus
nanopump (Eksigent) and analyzed on a TripleTOF 5600 Instrument
(AB SCIEX). The gradient was delivered at a flow rate of 200 nl/min
starting from 2% acetonitrile with 0.1% formic acid, ramping up to
35% acetonitrile with 0.1% formic acid over 90 min, followed by a
15-min cleanup at 80% acetonitrile with 0.1% formic acid and a
15-min equilibration period back to 2% acetonitrile with 0.1% formic
acid, for a total of 120 min. To minimize carryover between each sam-
ple, we washed the analytical column for 3 hours by running an
alternating sawtooth gradient from 35% acetonitrile with 0.1% formic
acid to 80% acetonitrile with 0.1% formic acid, holding each gradient
concentration for 5 min. Analytical column and instrument perfor-
mance were verified after each sample by loading 30 fmol of bovine ser-
um albumin (BSA) tryptic peptide standard (Michrom Bioresources
Inc.) with 60 fmol of a-casein tryptic digest and by running a short
30-min gradient. Time-of-flight (TOF) MS calibration was performed
onBSA reference ions before the next sample was run to adjust formass
drift and to verify peak intensity. The instrumentmethodwas set to dis-
covery or information-dependent acquisition mode, which consisted
of one 250-ms TOF MS1 survey scan from 400 to 1300 Da, followed by
twenty 100-ms MS2 candidate ion scans from 100 to 2000 Da in high-
sensitivity mode. Only ions with charges of 2+ to 4+, which exceeded a
threshold of 200 cps, were selected forMS2, and former precursors were
excluded for 10 s after one occurrence.
MS data analysis
MS data generated by TripleTOF 5600 were stored, searched, and ana-
lyzed using the ProHits laboratory information management system
platform (41). Within ProHits, the resulting WIFF files were first con-
verted into anMGF format using theWIFF2MGF converter and into an
mzML format using ProteoWizard (v3.0.4468) and the AB SCIEX MS
Data Converter (V1.3 beta) and then searched using Mascot (v2.3.02)
and Comet (v2012.02 rev.0). The spectra were searched with the RefSeq
database (version 53; 28 May 2014) acquired from the National Center
for Biotechnology Information (NCBI) against a total of 34,374 human
and adenovirus sequences supplemented with “common contaminants”
from the Max Planck Institute (http://141.61.102.106:8080/share.cgi?
ssid=0f2gfuB) and the Global Proteome Machine (www.thegpm.org/
crap/index.html). The database parameters were set to search for tryptic
cleavages, allowing up to two missed cleavage sites per peptide, with a
mass tolerance of 40 parts per million for precursors with charges of 2+
to 4+ and a tolerance of ±0.15 atomic mass units for fragment ions.
Variable modifications were selected for deamidated asparagine and
glutamine and for oxidized methionine. The results from each searchPicaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016engine were analyzed through TPP [the Trans-Proteomic Pipeline
(42) v4.6 OCCUPY rev 3] by means of the iProphet pipeline (43).
The resulting MS data were presented in a bar graph displaying the
ratio of spectral counts obtained for every BRD-containing protein in
the presence and absence of competing nonbiotinylated BSP. All MS
files used in this study were also deposited at MassIVE (http://massive.
ucsd.edu) under MassIVE ID MSV000079365.
Cell culture
Human cell lines (K562, KASUMI-1, and MV4;11) (44–46) were ob-
tained from the American Type Culture Collection and the Leibnitz In-
stitute Deutsche Sammlung von Mikroorganismen und Zellkulturen
(German Collection of Microorganisms and Cell Cultures) (www.dsmz.
de). Cell lines were cultured in RPMI 1640 medium (catalog no. 61870-
044; Gibco) containing 10% fetal calf serum (catalog no. 2-01F10-I; Bio-
Concept), penicillin (100 U/ml), and streptomycin (100 U/ml) (catalog
no. 15140-122;Gibco). TheOCI-AML3 cell line (47) wasmaintained in
aminimum essential medium (catalog no. BE12-169F; BioWhittaker)
supplemented with 20% heat-inactivated fetal calf serum (no. A15-152;
PAA). HEK293T cells were grown in Dulbecco’s modified Eagle’s me-
dium supplementedwith 5% fetal bovine serum (catalog no. 12483-020;
Gibco), 5% cosmic calf serum (catalog no. SH30087.03; HyClone), and
penicillin-streptomycin (catalogno. 30-002-CI;Corning).Cellswere grown
at 37°C in a humidified cabinet under 5% CO2 (Heraeus Function Line).
In vitro cytotoxicity assays
Cytotoxic activity of BSP on leukemic cell lines was assessed using two
different colorimetric assays. Cell viabilitywas assessed usingTrypan blue
(Sigma). Cells were harvested from exponential phase cultures and plated
on 96-well opaque flat-bottom plates at a cell density of 4 × 104 cells per
well (50 ml). After 2 to 4 hours of recovery, 50 ml of a medium containing
DMSO (vehicle) or the test compound was added to the wells. For each
concentration, cells were plated in quadruplicate. Cells were exposed to
the compound for 48 and 72 hours before 10 ml of WST-1 reagent (cat-
alog no. 05015944001; Roche) was added to every well. After 30 s on an
orbital shaker and further incubation for 2 hours, absorbance of the
samples was measured with an enzyme-linked immunosorbent assay
(ELISA) plate reader (Synergy H1 Hybrid Multi-Mode Microplate
Reader) at a wavelength of 450 versus 650 nm (background). Samples
were blanked with a control well, and the percentage of surviving cells
were compared to controls (fig. S3). Cytotoxic activity of JQ1 and BSP
on leukemic cell lines was also assessed using the colorimetric CellTiter
Aqueous Non-Radioactive Cell Proliferation Assay (Promega). Cell vi-
ability was assessed using Trypan blue (Sigma). Cells were harvested
from exponential phase cultures and plated on 96-well opaque flat-
bottom plates at a cell density of 2 × 105 cells per well (100 ml). After
2 to 4 hours of recovery, 100 ml of amediumcontainingDMSO(vehicle)
or the test compound was added to the wells. For each concentration,
cells were plated in triplicate. Cells were exposed to the compound for
72 hours before the addition of 40 ml of 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS), in the presence of phenazinemethosulfate (PMS) to each well.
After 30 s on an orbital shaker and further incubation for 2 hours, ab-
sorbance of the samples at 485 nm was measured with an ELISA plate
reader (PHERAstar; BMG LABTECH) (fig. S4A).
NCI-60 growth inhibition determination
BSP was submitted to the NCI Human Tumor Cell Line Screen
(https://dtp.cancer.gov/discovery_development/nci-60/) and profiled12 of 16
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 against 60 tumor cell lines, first at a single dose of 10 mMand then in a
serial dilution of five concentrations, following the NCI standard
screening protocol (48).
Binding against human recombinant ligands and ion
receptors (CEREP)
Selectivity profiling (ExpresSProfile) was performed on BSP against
104 ligand receptors, ion channels, and transport proteins by CEREP
using the manufacturer’s protocols. Data were analyzed in Microsoft
Excel (Microsoft Corp.).
Clonogenic and replating assays in methylcellulose
The impact of BSP on the clonogenic potential of cells was assessed
in methylcellulose cultures at different concentrations (0.1, 0.5, and
1.0 mM) or in DMSO (vehicle control). KASUMI-1 and MV4;11 cells
were plated in methylcellulose supplemented with human cytokines
(MethoCult H4535; STEMCELL Technologies), whereas K562 and
MV4;11 cells were plated in methylcellulose without additional cyto-
kines (5510; StemAlpha) at 2 × 103 cells per plate. All plates were incu-
bated at 37°C and 5% CO2 for 6 to 10 days before the number of
colonies was counted and before viable cells were harvested. Cytospots
were prepared by centrifuging 105 cells at 300 rpm for 3 min using a
Shandon Cytospin 3 centrifuge. Cytospots were stained with Wright-
Giemsa stain and analyzed with an Olympus BX62 or Nikon TI micro-
scope at ×60 magnification.
Cell cycle analysis
Cells were treated in liquid culture with increasing concentrations of
BSP or JQ1. After 48 hours, cells were washed twice with PBS, fixed
with ice-cold 70% ethanol, and stained in a solution containing pro-
pidium iodide (50 mg/ml; P4684; Sigma), ribonuclease (10 mg/ml;
10109142001; Roche), and 1% Triton X-100 in PBS. DNA content
was measured on an Accuri C6 cytometer (BD Biosciences), and data
were analyzed using the FlowJo software suite (TreeStar Inc.).
Experiments were repeated three times.
Inhibitor combination analysis
Cell lines (MV4;11 and K562 from the log growth phase in RPMI–10%
fetal calf serum) were treated with inhibitors (JQ1 or BSP) individually
or in combination [JQ1: 0.7 to 11,392 nM (15× concentration); BSP: 37
to 4728 nM (8× concentration)]. Cell survival was determined using a
WST-1 assay (no. 05015944001; Roche). Raw data were blanked and
normalized to DMSO-treated controls. Data sets were log-transformed
and normalized individually, and the combination index (49) was
calculated for each inhibitor combination using the CompuSyn
software suite (ComboSyn Inc.).
Fluorescence recovery after photobleaching
FRAP studies were performed using a protocol previously described by
Philpott et al. (50). In brief, U2OS cells were transfected (Lipofectamine;
Invitrogen) with mammalian overexpression constructs encoding GFP
chimeras with BRD4 or BRD9. The FRAP and imaging system con-
sisted of a Zeiss LSM 710 scanhead (Zeiss GmbH) coupled to an
inverted Zeiss Axio Observer.Z1 microscope equipped with a high–
numerical aperture (1.3) ×40 oil immersion objective (Zeiss GmbH)
equipped with a heated chamber set to 37°C. FRAP and GFP fluores-
cence imaging were carried out with an argon-ion laser (488 nm) and
with a piezomultiplier tube detector set to detect fluorescence between
500 and 550 nm. A 5-mm2 region of the nucleus was selected, and thePicaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016region was bleached after five prescans. A time-lapse series was then
taken to record GFP recovery using 1% of the power used for bleaching
at an interval of 0.25 s. The image data sets and fluorescence recovery
data were exported from the ZEN 2010 microscope control software
into Origin v.7. The average intensity at each imaging time point was
measured for three regions of interest: the bleached region (It), the total
cell nucleus (Tt), and a random region outside the cell for background
subtraction (BG). The relative fluorescence signal in the bleached region
was calculated for each time point t, with the following formula (51)
ðTaverage prebleach  BGÞðIt  BGÞ=ðTt– BGÞðIaverage prebleach– BGÞ
The baseline was normalized to zero, and the prebleachwas normal-
ized to 1. Half times of recovery were calculated from the individual
curves and presented as the mean. Paired t tests were used to generate
P values for comparisons between two groups.
RNA extraction
Cells were seeded at 2 × 105 cells/ml on the day before treatment. Treat-
mentswere performed so that a final concentration of 0.1%DMSO (cat-
alog no. D1435; Sigma) was achieved, and cells were incubated with the
vehicle or test compound for 6 hours before isolation of RNA. Total
RNA was isolated using a standard TRIzol (Invitrogen) protocol and
prepared using RNeasy columns (catalog no. 74106 plus; Qiagen).
RNA was quantified using a NanoDrop spectrophotometer (model
ND1000; Thermo Fisher Scientific), and integrity was assessed on a
BioAnalyzer (2100; Agilent Laboratories). All samples had an RNA in-
tegrity number of ≥9.
Genome-wide expression analysis
mRNA samples were processed using the Illumina TotalPrep-96 RNA
Amplification Kit followed by the Illumina Whole-Genome Gene Ex-
pression Direct Hybridization Assay. The labeled complementary RNA
was then hybridized on IlluminaHumanHT-12 v4 bead chips (Illumina
Inc.). Chips were processed on an Illumina iScan Scanner, and the Illu-
mina GenomeStudio (v.1.9.0; Illumina Inc.) was used to generate bead
files. GenomeStudio data were processed in R (v.3.2) (52) using Biocon-
ductor (v.3.1) (53) and the lumi package (v.2.20.2) (54). Quality controls
were carried out using the arrayQualityMetrics package (v.3.24.0) (55),
taking into account array intensity distributions, distance between ar-
rays, and variance mean dependence. Principal components analysis
was used to decide which arrays to process together. Background cor-
rection followed by variance-stabilizing transform (56) and quantiles
between microarrays normalization were carried out with the lumi
package. From the 47,231 probe sets available on the HumanHT12
V4 chip, removal of unexpressed probes resulted in 24,283 probe sets.
A linear model was applied using the limma package (v.3.24.13) (57),
followed by empirical Bayesian analysis, to determine differential expres-
sion between untreated and treated samples. Genes were considered to
be differentially expressed if the adjusted P value [calculated using the
Benjamini-Hochberg method (58) to minimize false discovery rate
(FDR)] was less than 0.05 and the mean level of expression was greater
than 1.5-fold. GeneOntology (GO) enrichment analysis was performed
with the topGOpackage (v.2.20.0) (59) using theweight01 algorithm and
Fisher’s exact test to calculate the significance of aGO term.A cutoff value
of 0.01 was imposed on the adjusted P values to report enriched terms.
Genes exhibiting a differential expression upon BSP or JQ1 treatment
(Benjamini-Hochberg adjusted P < 0.01) were further subjected to13 of 16
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 enrichment analyses in the MetaCore software suite (MetaCore
v.6.19.65960; Thomson Reuters) to reveal signaling and metabolic
pathways, as well as cell process networks overrepresented in the dif-
ferentially expressed gene sets. P values for pathway enrichment
analysis were calculated using the formula for hypergeometric
distribution, reflecting the probability for a pathway to arise by
chance. Statistically enriched pathways and networks were identified
using a threshold FDR of 0.001. Gene expression data have been
deposited in NCBI’s Gene Expression Omnibus and are accessible
through GEO Series accession number GSE78830.
Gene set analysis and GSEA
Gene expression data were further filtered to remove unannotated
genes, resulting in 18,754 probes. Multiprobe profiles were averaged
using the collapseRows R function (60), resulting in 13,620 unique
genes, which were imported into the Broad GSEA suite (v.2.2.0)
(61) as a collapsed set. Gene set analysis was performed with the piano
package (v.1.8.2) (62) using the MaxMean method (63), with 1000
permutations and with minimum and maximum gene sets of 15
and 500, respectively, against the 50 hallmark (h) gene sets from the
MSigDB (v.5.0). Resulting gene sets with a nominal P value of 0.05
were considered significant. Distinct nondirectional and directional
network maps were visualized with the piano package.
GSEA was performed with the Broad GSEA suite (v.2.2.0) (61) in a
collection of 4725 curated gene sets (c2), 615 transcription factors (c3),
and 50 hallmarks (h) from MSigDB (v.5.0). Gene sets with less than
15 genes or more than 500 genes were excluded from the analysis,
whereas gene sets with an FDR of ≤0.25 and a nominal P value of
≤0.05 were considered significant. Gene ranking was performed with
the weighted enrichment score using a two-sided signal-to-noise ratio,
and P values were calculated using 1000 permutations of the gene set.
JQ1 gene signatures
TheAML JQ1 signaturewas constructed using the gene expression data
(GEOdata set: GSE29799) after a 24-hour treatment of THP1 cells with
250 nM JQ1, as reported by Zuber et al. (6). Differentially expressed
genes with an adjusted P value of <0.001 and a log fold change of >2,
which were down-regulated (185 genes), were used as a ranked list to
construct a gene set for subsequent GSEA. A smaller JQ1 signature con-
sisting of 36 genes previously reported by Puissant et al. (27) to be
down-regulated by JQ1 in neuroblastoma, multiple myeloma, and
AML was also used to construct a gene set for subsequent GSEA.
Quantitative real-time polymerase chain reaction
One microgram of RNA was used to prepare cDNA using the iScript
cDNA synthesis kit (catalog no. 1708891; Bio-Rad) according to the
manufacturer’s instructions. The resulting cDNA was diluted 1:10
before qRT-PCR was performed. Samples were prepared on 384-well
plates with a final reaction volume of 10 ml containing SYBR Select
Master Mix (catalog no. 4472908; Thermo Fisher Scientific), 0.4 mM
forward and reverse primers, and 2 ml of diluted cDNA. All reactions
were run on a QuantStudio 6 Flex Real-Time PCR system (Thermo
Fisher Scientific) under the following conditions: 1 cycle at 50°C for
2min and then 1 cycle at 95°C for 2min, followed by 40 cycles at 95°C
for 15 s and then60°C for 1min each.Datawere analyzedusing the 2−DDCT
method (64), and sample normalization was performed using 18S ribo-
somal RNA as the endogenous control and SDHA as the reference gene.
Values are presented as means ± SD from three biological replicates.
P values are presented such that ****P < 0.001, ***P < 0.005, **P < 0.01,Picaud et al. Sci. Adv. 2016;2 : e1600760 12 October 2016and *P < 0.05 and were evaluated with one-step ANOVA followed by
Dunnett’s test (performed inGraphPad Prism v.6). Primers are listed in
table S5.SUPPLEMENTARY MATERIALS
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